Skip to main content
Erschienen in: Calcified Tissue International 6/2021

08.02.2021 | Original Research

Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France

verfasst von: Maud Jalabert, Salah Ferkal, Jean-Claude Souberbielle, Emilie Sbidian, Arthur Mageau, Florent Eymard, Philippe Le Corvoisier, Laurence Allanore, Xavier Chevalier, Pierre Wolkenstein, Sandra Guignard

Erschienen in: Calcified Tissue International | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

There is an increased risk of osteoporosis and an abnormal bone turn over in neurofibromatosis 1 (NF1). Our objective is to evaluate bone status in NF1 and to look for associations with cutaneous phenotype. We conducted a descriptive, monocentric study. We included 60 NF1 women, 18–51 years old, non-menopausal, divided in 2 groups: «at risk phenotype» (ARP) composed by 30 patients with at least 2 subcutaneous neurofibromas (SC-NF) and «classical phenotype» (CP) composed by 30 patients with none or 1 SC-NF. We evaluated low bone mineral density (BMD) risk factors and measured BMD, calcium and phosphorus homeostasis and bone turnover markers. Before 50 years old, Z-score has to be used to assess BMD. Z-score < − 2 is below expected range and represents 2.5% of the population. There was no difference between the two groups. Overall, Z-scores were low and 5 patients had a Z-score < − 2 (8.3%), which is 3 times general population low BMD frequency. 10 fragility fractures occurred in 8 patients, among which 2 were vertebral fractures. 85% had low calcium intake. 12 patients had hypophosphoremia, 25 elevated PTH. Vitamin D levels were low for 86.4%. 41 patients (69.5%) had at least one abnormal bone turnover markers. Low BMD is 3.3 times more frequent in NF1 than in general population, with high fracture risk, regardless of the skin phenotype, classical or at risk, because of high bone turn over and secondary hyperparathyroidism due to vitamin D deficiency and poor calcium intake.
Literatur
1.
Zurück zum Zitat Uusitalo E, Leppävirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Investig Dermatol 135(3):904–906PubMedCrossRef Uusitalo E, Leppävirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Investig Dermatol 135(3):904–906PubMedCrossRef
2.
Zurück zum Zitat Hirbe AC, Gutmann DH (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 13(8):834–843PubMedCrossRef Hirbe AC, Gutmann DH (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 13(8):834–843PubMedCrossRef
3.
Zurück zum Zitat Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primer 23(3):17004CrossRef Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primer 23(3):17004CrossRef
5.
Zurück zum Zitat Pinson S, Wolkenstein P (2005) Neurofibromatosis type 1 or Von Recklinghausen’s disease. Rev Med Interne 26(3):196–215PubMedCrossRef Pinson S, Wolkenstein P (2005) Neurofibromatosis type 1 or Von Recklinghausen’s disease. Rev Med Interne 26(3):196–215PubMedCrossRef
6.
Zurück zum Zitat Cunha KSG, Caruso AC, de Faria PAS, da Silva LE, Pires ARC, Geller M et al (2012) Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival. Clinics 67(8):963–968PubMedPubMedCentralCrossRef Cunha KSG, Caruso AC, de Faria PAS, da Silva LE, Pires ARC, Geller M et al (2012) Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival. Clinics 67(8):963–968PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Khosrotehrani K, Bastuji-Garin S, Zeller J, Revuz J, Wolkenstein P (2003) Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol 139(2):187–191PubMedCrossRef Khosrotehrani K, Bastuji-Garin S, Zeller J, Revuz J, Wolkenstein P (2003) Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol 139(2):187–191PubMedCrossRef
8.
Zurück zum Zitat Poyrazoğlu HG, Baş VN, Arslan A, Bastug F, Canpolat M, Per H et al (2017) Bone mineral density and bone metabolic markers’ status in children with neurofibromatosis type 1. J Pediatr Endocrinol Metab 30(2):175–180PubMedCrossRef Poyrazoğlu HG, Baş VN, Arslan A, Bastug F, Canpolat M, Per H et al (2017) Bone mineral density and bone metabolic markers’ status in children with neurofibromatosis type 1. J Pediatr Endocrinol Metab 30(2):175–180PubMedCrossRef
9.
Zurück zum Zitat Yilmaz K, Ozmen M, Bora Goksan S, Eskiyurt N (2007) Bone mineral density in children with neurofibromatosis 1. Acta Paediatr Oslo Nor 1992 96(8):1220–2 Yilmaz K, Ozmen M, Bora Goksan S, Eskiyurt N (2007) Bone mineral density in children with neurofibromatosis 1. Acta Paediatr Oslo Nor 1992 96(8):1220–2
10.
Zurück zum Zitat Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC et al (2007) Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150(1):83–88PubMedPubMedCentralCrossRef Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC et al (2007) Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150(1):83–88PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG (2007) Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 27(4):472–475PubMedCrossRef Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG (2007) Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 27(4):472–475PubMedCrossRef
12.
Zurück zum Zitat Lammert M, Kappler M, Mautner V-F, Lammert K, Störkel S, Friedman JM et al (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 16(9):1161–1166CrossRef Lammert M, Kappler M, Mautner V-F, Lammert K, Störkel S, Friedman JM et al (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 16(9):1161–1166CrossRef
13.
Zurück zum Zitat Tucker T, Schnabel C, Hartmann M, Friedrich RE, Frieling I, Kruse H-P et al (2009) Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 46(4):259–265PubMedCrossRef Tucker T, Schnabel C, Hartmann M, Friedrich RE, Frieling I, Kruse H-P et al (2009) Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 46(4):259–265PubMedCrossRef
14.
Zurück zum Zitat Heervä E, Koffert A, Jokinen E, Kuorilehto T, Peltonen S, Aro HT et al (2012) A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 27(11):2333–2337PubMedCrossRef Heervä E, Koffert A, Jokinen E, Kuorilehto T, Peltonen S, Aro HT et al (2012) A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 27(11):2333–2337PubMedCrossRef
15.
Zurück zum Zitat Heervä E, Leinonen P, Kuorilehto T, Peltonen S, Pöyhönen M, Väänänen K et al (2013) Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years. Calcif Tissue Int 92(1):23–27PubMedCrossRef Heervä E, Leinonen P, Kuorilehto T, Peltonen S, Pöyhönen M, Väänänen K et al (2013) Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years. Calcif Tissue Int 92(1):23–27PubMedCrossRef
16.
Zurück zum Zitat Heervä E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, Väänänen K et al (2010) Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47(3):583–590PubMedCrossRef Heervä E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, Väänänen K et al (2010) Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47(3):583–590PubMedCrossRef
17.
Zurück zum Zitat Schindeler A, Little DG (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42(4):616–622PubMedCrossRef Schindeler A, Little DG (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42(4):616–622PubMedCrossRef
18.
Zurück zum Zitat Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE et al (2010) High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 21(1):119–127PubMedCrossRef Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE et al (2010) High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 21(1):119–127PubMedCrossRef
19.
Zurück zum Zitat Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M et al (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94(1):105–111PubMedPubMedCentralCrossRef Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M et al (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94(1):105–111PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Lammert M, Friedman JM, Roth HJ, Friedrich RE, Kluwe L, Atkins D et al (2006) Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet 43(10):810–813PubMedPubMedCentralCrossRef Lammert M, Friedman JM, Roth HJ, Friedrich RE, Kluwe L, Atkins D et al (2006) Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet 43(10):810–813PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G et al (2012) Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res 304(4):325–331PubMedCrossRef Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G et al (2012) Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res 304(4):325–331PubMedCrossRef
22.
Zurück zum Zitat Schnabel C, Dahm S, Streichert T, Thierfelder W, Kluwe L, Mautner VF (2014) Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1. Clin Biochem 47(7–8):560–563PubMedCrossRef Schnabel C, Dahm S, Streichert T, Thierfelder W, Kluwe L, Mautner VF (2014) Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1. Clin Biochem 47(7–8):560–563PubMedCrossRef
23.
Zurück zum Zitat Souza Mario Bueno L, Rosset C, Aguiar E, Pereira F de S, Izetti Ribeiro P, Scalco R et al (2015) Vitamin D status and VDR genotype in NF1 patients: a case-control study from Southern Brazil. Int J Endocrinol 2015:1–9CrossRef Souza Mario Bueno L, Rosset C, Aguiar E, Pereira F de S, Izetti Ribeiro P, Scalco R et al (2015) Vitamin D status and VDR genotype in NF1 patients: a case-control study from Southern Brazil. Int J Endocrinol 2015:1–9CrossRef
24.
Zurück zum Zitat Hockett CW, Eelloo J, Huson SM, Roberts SA, Berry JL, Chaloner C et al (2013) Vitamin D status and muscle function in children with neurofibromatosis type 1 (NF1). J Musculoskelet Neuronal Interact 13(1):111–119PubMed Hockett CW, Eelloo J, Huson SM, Roberts SA, Berry JL, Chaloner C et al (2013) Vitamin D status and muscle function in children with neurofibromatosis type 1 (NF1). J Musculoskelet Neuronal Interact 13(1):111–119PubMed
25.
Zurück zum Zitat Schnabel C, Jett K, Friedman JM, Frieling I, Kruse H-P, Mautner V (2013) Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study. Jt Bone Spine 80(3):315–319CrossRef Schnabel C, Jett K, Friedman JM, Frieling I, Kruse H-P, Mautner V (2013) Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study. Jt Bone Spine 80(3):315–319CrossRef
26.
Zurück zum Zitat Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C et al (1991) Evaluation of the calcium content of diet by frequential self-questionnaire. Rev Rhum Mal Osteoartic 58(2):99–103PubMed Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C et al (1991) Evaluation of the calcium content of diet by frequential self-questionnaire. Rev Rhum Mal Osteoartic 58(2):99–103PubMed
27.
Zurück zum Zitat Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S et al (2006) Traitement médicamenteux de l’ostéoporose post-ménopausique. Presse Médicale 35(10):1529–1539CrossRef Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S et al (2006) Traitement médicamenteux de l’ostéoporose post-ménopausique. Presse Médicale 35(10):1529–1539CrossRef
28.
Zurück zum Zitat Souberbielle J-C, Cavalier E, Delanaye P, Massart C, Brailly-Tabard S, Cormier C et al (2015) Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations. Clin Chim Acta Int J Clin Chem 451(Pt B):149–153CrossRef Souberbielle J-C, Cavalier E, Delanaye P, Massart C, Brailly-Tabard S, Cormier C et al (2015) Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations. Clin Chim Acta Int J Clin Chem 451(Pt B):149–153CrossRef
29.
Zurück zum Zitat Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler DL et al (2008) Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 19(10):1369–1378CrossRef Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler DL et al (2008) Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 19(10):1369–1378CrossRef
30.
Zurück zum Zitat Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res Off J Am Soc Bone Miner Res 11(7):984–996CrossRef Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res Off J Am Soc Bone Miner Res 11(7):984–996CrossRef
31.
Zurück zum Zitat Koga M, Yoshida Y, Imafuku S (2016) Nutritional, muscular and metabolic characteristics in patients with neurofibromatosis type 1. J Dermatol 43(7):799–803PubMedCrossRef Koga M, Yoshida Y, Imafuku S (2016) Nutritional, muscular and metabolic characteristics in patients with neurofibromatosis type 1. J Dermatol 43(7):799–803PubMedCrossRef
33.
Zurück zum Zitat Gupta A, Dwivedi A, Patel P, Gupta S (2015) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis: case report and literature review. Indian J Radiol Imaging 25(1):63–66PubMedPubMedCentralCrossRef Gupta A, Dwivedi A, Patel P, Gupta S (2015) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis: case report and literature review. Indian J Radiol Imaging 25(1):63–66PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Konishi K, Nakamura M, Yamakawa H, Suzuki H, Saruta T, Hanaoka H et al (1991) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. Am J Med Sci 301(5):322–328PubMedCrossRef Konishi K, Nakamura M, Yamakawa H, Suzuki H, Saruta T, Hanaoka H et al (1991) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. Am J Med Sci 301(5):322–328PubMedCrossRef
35.
Zurück zum Zitat Souberbielle J-C (2016) Epidemiology of vitamin-D deficiency. Geriatr Psychol Neuropsychiatr Vieil 1(14):7–15 Souberbielle J-C (2016) Epidemiology of vitamin-D deficiency. Geriatr Psychol Neuropsychiatr Vieil 1(14):7–15
36.
Zurück zum Zitat Stevenson DA, Schwarz EL, Viskochil DH, Moyer-Mileur LJ, Murray M, Firth SD et al (2008) Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res 63(6):697–701PubMedPubMedCentralCrossRef Stevenson DA, Schwarz EL, Viskochil DH, Moyer-Mileur LJ, Murray M, Firth SD et al (2008) Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res 63(6):697–701PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Heervä E, Huilaja L, Leinonen P, Peltonen S, Peltonen J (2014) Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. Calcif Tissue Int 94(6):608–612PubMedCrossRef Heervä E, Huilaja L, Leinonen P, Peltonen S, Peltonen J (2014) Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. Calcif Tissue Int 94(6):608–612PubMedCrossRef
38.
Zurück zum Zitat Benlidayi IC, Ortac EA, Kozanoglu E (2015) Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine. Acta Clin Belg 70(2):130–132PubMedCrossRef Benlidayi IC, Ortac EA, Kozanoglu E (2015) Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine. Acta Clin Belg 70(2):130–132PubMedCrossRef
39.
Zurück zum Zitat Heervä E, Peltonen S, Svedström E, Aro HT, Väänänen K, Peltonen J (2012) Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone 50(3):798–803PubMedCrossRef Heervä E, Peltonen S, Svedström E, Aro HT, Väänänen K, Peltonen J (2012) Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone 50(3):798–803PubMedCrossRef
40.
Zurück zum Zitat Rietman AB, Oostenbrink R, Bongers S, Gaukema E, van Abeelen S, Hendriksen JG et al (2017) Motor problems in children with neurofibromatosis type 1. J Neurodev Disord 9:19PubMedPubMedCentralCrossRef Rietman AB, Oostenbrink R, Bongers S, Gaukema E, van Abeelen S, Hendriksen JG et al (2017) Motor problems in children with neurofibromatosis type 1. J Neurodev Disord 9:19PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Summers MA, Rupasinghe T, Vasiljevski ER, Evesson FJ, Mikulec K, Peacock L et al (2018) Dietary intervention rescues myopathy associated with neurofibromatosis type 1. Hum Mol Genet 27(4):577–88PubMedCrossRef Summers MA, Rupasinghe T, Vasiljevski ER, Evesson FJ, Mikulec K, Peacock L et al (2018) Dietary intervention rescues myopathy associated with neurofibromatosis type 1. Hum Mol Genet 27(4):577–88PubMedCrossRef
42.
Zurück zum Zitat Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK et al (2009) Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 149A(10):2327–2338PubMedCrossRef Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK et al (2009) Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 149A(10):2327–2338PubMedCrossRef
43.
Zurück zum Zitat Pecoraro A, Arehart E, Gallentine W, Radtke R, Smith E, Pizoli C et al (2017) Epilepsy in neurofibromatosis type 1. Epilepsy Behav EB 73:137–141CrossRef Pecoraro A, Arehart E, Gallentine W, Radtke R, Smith E, Pizoli C et al (2017) Epilepsy in neurofibromatosis type 1. Epilepsy Behav EB 73:137–141CrossRef
44.
Zurück zum Zitat Abdolrahimzadeh B, Piraino DC, Albanese G, Cruciani F, Rahimi S (2016) Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography. Clin Ophthalmol Auckl NZ 13(10):851–860 Abdolrahimzadeh B, Piraino DC, Albanese G, Cruciani F, Rahimi S (2016) Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography. Clin Ophthalmol Auckl NZ 13(10):851–860
Metadaten
Titel
Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France
verfasst von
Maud Jalabert
Salah Ferkal
Jean-Claude Souberbielle
Emilie Sbidian
Arthur Mageau
Florent Eymard
Philippe Le Corvoisier
Laurence Allanore
Xavier Chevalier
Pierre Wolkenstein
Sandra Guignard
Publikationsdatum
08.02.2021
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 6/2021
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-021-00807-6

Weitere Artikel der Ausgabe 6/2021

Calcified Tissue International 6/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.